{"id":77545,"date":"2017-02-10T15:50:20","date_gmt":"2017-02-10T15:50:20","guid":{"rendered":"http:\/\/humanitasnet-new.local\/cure\/hronichna-mijeloidna-leukemija\/"},"modified":"2017-02-10T15:50:20","modified_gmt":"2017-02-10T15:50:20","slug":"hronichna-mijeloidna-leukemija","status":"publish","type":"cure","link":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/treatments\/hronichna-mijeloidna-leukemija\/","title":{"rendered":"Hroni\u010dna mijeloidna leukemija"},"content":{"rendered":"<h1>Hroni\u010dna mijeloidna leukemija<\/h1>\n<p>&nbsp;<\/p>\n<h2 id=\"sta-je-hronicna-mijeloidna-leukemija\">\u0160ta je hroni\u010dna mijeloidna leukemija?<\/h2>\n<p>Leukemija je hematolo\u0161ki malignitet (rak krvi) koji se razvija u ko\u0161tanoj sr\u017ei, krvi, limfnom sistemu i drugim tkivima. Tipovi leukemija obi\u010dno su podeljeni na akutni i hroni\u010dni zavisno od brzine progresije bolesti.<\/p>\n<p>Uop\u0161teno govore\u0107i, govorimo o leukemiji u prisustvu biolo\u0161kih promena u krvnim \u0107elijama (eritrocita, leukocita i trombocita) koje uzrokuju rast i nekontrolisano \u0161irenje samih \u0107elija. Naziv poti\u010de od gr\u010dke re\u010di leukemia Leucos = bela, jer bolest po\u010dinje u belim krvnim zrncima koji su odgovorni za borbu protiv infekcija, koji se obi\u010dno reprodukuju u skladu sa potrebama organizma.<\/p>\n<p>Kod pacijenata sa leukemijom ko\u0161tana sr\u017e proizvodi veliki broj abnormalnih belih krvnih zrnaca koji imaju genetske mutacije u DNK, a samim tim ne rade ispravno. Uzroci ove bolesti jo\u0161 ne razumeju u potpunosti ali izgleda da su uklju\u010deni i genetski i ekolo\u0161ki faktori.<\/p>\n<p>Hroni\u010dna vrsta leukemije je \u010de\u0161\u0107i kod odraslih. Naj\u010de\u0161\u0107i oblici su hroni\u010dna limfocitna leukemija (CLL) i hroni\u010dna mijeloidna leukemija (CML): mo\u017eda bi bilo prikladnije da se koristi re\u010d &#8220;enzootski&#8221; umesto &#8220;leukemije&#8221; s obzirom na definitivne razlike u pona\u0161anju, odgovoru na terapije i prognoze kod akutnih oblika leukemije.<\/p>\n<p>CML je veoma \u010desta kod odraslih, i veoma retka kod dece, sa prose\u010dnom staro\u0161\u0107u od oko 60 godina i u\u010destalo\u0161\u0107u u populaciji od oko 2,3 novih slu\u010dajeva godi\u0161nje na 100.000 stanovnika, \u0161to je o\u010digledni rast s obzirom na prose\u010dnu porast \u017eivotnog veka.<\/p>\n<p>Osnovna karakteristika ove bolesti je abnormalna proliferacija zrelih belih krvnih zrnaca, i veoma retko trombocita, koji se naj\u010de\u0161\u0107e na\u0111u slu\u010dajno povodom periodi\u010dnih kontrolnih pregleda. U pro\u0161losti, kada je bilo manje uobi\u010dajeno da se rade pregledi, CML je bila dijagnostikovana zbog ose\u0107aja te\u017eine na levoj strani zbog rasta veli\u010dine slezine (splenomegalija) koja je jo\u0161 uvek povezana sa naprednijim fazama CML-a.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"kako-je-nastala-ova-bolest\">Kako je nastala ova bolest?<\/h2>\n<p>U 1960 je do\u0161lo do studije hromozoma (kariotipizacija) koje su dovele dva lekara iz Filadelfije da saznaju da pacijenti sa CML imaju hromozom 22 koji je kra\u0107i nego \u0161to je uobi\u010dajeno. Ovaj oblik &#8220;kratkih&#8221; hromozoma 22 je nazvan Filadelfija hromozom (Ph hromozom). Naknadne studije su pokazale da je hromozom 9 isto druaga\u010diji kod bolesnika sa CML. Utvr\u0111eno je da izme\u0111u hromozoma 9 i hromozoma 22 postoji uzajamna razmena hromozomske materije: naime, da je jedan deo hromozoma 9 povezan na hromozomom 22 i obrnuto (translokacija). Rezultati su bili da su sve leukemijske \u0107elije bile pozitivne za translokaciju 9 i 22 hromozoma dok su ostale \u0107elije kostiju i tkiva imali normalne kariotipe.<\/p>\n<p>U 80-im godinama je bilo poznato da je translokacija 9; 22 uklju\u010divala uglavnom dva gena &#8211; BCR gen (hromozom 22) i ABL gen (hromozom 9) &#8211; \u0161to je dovelo do takozvane fuzije gena BCR-ABL. Ovo poslednje stvara abnormalni protein (nije prisutan kod zdravih ljudi), koji zna\u010dajno uti\u010de na \u0107elijski ciklus dovo\u0111enje leukemijskih \u0107elija u slabo kontrolisanu proliferaciju. Abnormalni protein koji sledi je &#8220;tirozin kinaza&#8221; i nastavlja do drugih proteina u \u0107eliji: znanje ovog mehanizma je dovela istra\u017eiva\u010de do otkri\u0107a specifi\u010dnih lekova za selektivnu inhibiciju njene funkcije (inhibitori tirozin kinaze) koji su revolucionirali le\u010denje CML-a sa izvandrednim uspehom.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"koji-su-faktori-rizika-za-cml\">Koji su faktori rizika za CML?<\/h2>\n<p>Neki faktori mogu pove\u0107ati rizik od pojave odre\u0111enih vrsta leukemije:<\/p>\n<p>\u2022 Terapije za rak kao \u0161to su odre\u0111ene vrste hemoterapije ili terapije zra\u010denjem.<\/p>\n<p>\u2022 Izlaganje visokom nivou zra\u010denja.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"pevencija\">Pevencija<\/h2>\n<p>Osim izbegavanja izlo\u017eenosti radijaciji ili kancerogenih hemikalija, ne postoji specifi\u010dan na\u010din (stil \u017eivota, navike u ishrani ili izlo\u017eenost hemijskim agensima) kako bi se spre\u010dila CML jer su ta\u010dni uzroci nepoznati.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-77545","cure","type-cure","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hroni\u010dna mijeloidna leukemija - Humanitas.net<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"sr_RS\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hroni\u010dna mijeloidna leukemija - Humanitas.net\" \/>\n<meta property=\"og:description\" content=\"Hroni\u010dna mijeloidna leukemija &nbsp; \u0160ta je hroni\u010dna mijeloidna leukemija? Leukemija je hematolo\u0161ki malignitet (rak krvi) koji se razvija u ko\u0161tanoj sr\u017ei, krvi, limfnom sistemu i drugim tkivima. Tipovi leukemija obi\u010dno su podeljeni na akutni i hroni\u010dni zavisno od brzine progresije bolesti. Uop\u0161teno govore\u0107i, govorimo o leukemiji u prisustvu biolo\u0161kih promena u krvnim \u0107elijama (eritrocita, leukocita [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Humanitas.net\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HumanitasInternational\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@humanitasmilano\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/\",\"name\":\"Hroni\u010dna mijeloidna leukemija - Humanitas.net\",\"isPartOf\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#website\"},\"datePublished\":\"2017-02-10T15:50:20+00:00\",\"dateModified\":\"2017-02-10T15:50:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/#breadcrumb\"},\"inLanguage\":\"sr-RS\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/humanitas-net.humweb.webiz.team\/sr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trattamenti\",\"item\":\"https:\/\/humanitas-net.humweb.webiz.team\/cure\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Hroni\u010dna mijeloidna leukemija\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#website\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/\",\"name\":\"Humanitas.net\",\"description\":\"Humanitas Hospital\",\"publisher\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/humanitas-net.humweb.webiz.team\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sr-RS\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#organization\",\"name\":\"Humanitas\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sr-RS\",\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg\",\"contentUrl\":\"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg\",\"width\":1,\"height\":1,\"caption\":\"Humanitas\"},\"image\":{\"@id\":\"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/HumanitasInternational\/\",\"https:\/\/x.com\/humanitasmilano\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hroni\u010dna mijeloidna leukemija - Humanitas.net","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"sr_RS","og_type":"article","og_title":"Hroni\u010dna mijeloidna leukemija - Humanitas.net","og_description":"Hroni\u010dna mijeloidna leukemija &nbsp; \u0160ta je hroni\u010dna mijeloidna leukemija? Leukemija je hematolo\u0161ki malignitet (rak krvi) koji se razvija u ko\u0161tanoj sr\u017ei, krvi, limfnom sistemu i drugim tkivima. Tipovi leukemija obi\u010dno su podeljeni na akutni i hroni\u010dni zavisno od brzine progresije bolesti. Uop\u0161teno govore\u0107i, govorimo o leukemiji u prisustvu biolo\u0161kih promena u krvnim \u0107elijama (eritrocita, leukocita [&hellip;]","og_url":"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/","og_site_name":"Humanitas.net","article_publisher":"https:\/\/www.facebook.com\/HumanitasInternational\/","twitter_card":"summary_large_image","twitter_site":"@humanitasmilano","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/","url":"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/","name":"Hroni\u010dna mijeloidna leukemija - Humanitas.net","isPartOf":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#website"},"datePublished":"2017-02-10T15:50:20+00:00","dateModified":"2017-02-10T15:50:20+00:00","breadcrumb":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/#breadcrumb"},"inLanguage":"sr-RS","potentialAction":[{"@type":"ReadAction","target":["https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/humanitas-net.humweb.webiz.team\/treatments\/chronic-myeloid-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/"},{"@type":"ListItem","position":2,"name":"Trattamenti","item":"https:\/\/humanitas-net.humweb.webiz.team\/cure\/"},{"@type":"ListItem","position":3,"name":"Hroni\u010dna mijeloidna leukemija"}]},{"@type":"WebSite","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#website","url":"https:\/\/humanitas-net.humweb.webiz.team\/","name":"Humanitas.net","description":"Humanitas Hospital","publisher":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/humanitas-net.humweb.webiz.team\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sr-RS"},{"@type":"Organization","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#organization","name":"Humanitas","url":"https:\/\/humanitas-net.humweb.webiz.team\/","logo":{"@type":"ImageObject","inLanguage":"sr-RS","@id":"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/","url":"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg","contentUrl":"https:\/\/humanitas-net.humweb.webiz.team\/wp-content\/uploads\/2025\/01\/new-humanitas-logo-1.svg","width":1,"height":1,"caption":"Humanitas"},"image":{"@id":"https:\/\/humanitas-net.humweb.webiz.team\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/HumanitasInternational\/","https:\/\/x.com\/humanitasmilano"]}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/cure\/77545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/cure"}],"about":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/types\/cure"}],"wp:attachment":[{"href":"https:\/\/humanitas-net.humweb.webiz.team\/sr\/wp-json\/wp\/v2\/media?parent=77545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}